Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.

The company is based in Irvine, California.

AEON Biopharma, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Marc Forth

Contact Details

Address: 5 Park Plaza, Suite 1750 Irvine, California 92614 United States
Phone	(949) 354-6499
Website	aeonbiopharma.com

Stock Details

Ticker Symbol	AEON
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001837607
CUSIP Number	00775E102
ISIN Number	US00791X1000
Employer ID	85-3940478
SIC Code	2834

Key Executives

Name	Position
Marc Forth	Principal Financial Officer, President, Chief Executive Officer and Director
Alex Wilson	Executive Vice President, Chief Legal Officer and Corporate Secretary
Dr. Chad K. Oh M.D.	Chief Medical Officer
Jennifer Sy	Principal Accounting Officer

Latest SEC Filings

Date	Type	Title
Dec 20, 2024	8-K	Current Report
Nov 14, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024	424B3	Prospectus
Nov 13, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report
Oct 7, 2024	8-K	Current Report
Aug 21, 2024	EFFECT	Notice of Effectiveness
Aug 21, 2024	424B5	Filing
Aug 19, 2024	UPLOAD	Filing
Aug 15, 2024	S-3	Registration statement under Securities Act of 1933

View All SEC Filings